Drug Trial Radar · NCT02631642
A Study of HMPL-689 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 23, 2016
Primary completion
Oct 26, 2016
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers
Conditions
- Healthy Volunteers
Interventions
HMPL-689Drug
selective PI3Kδ inhibitor
HMPL-689 placeboDrug
placebo of HMPL-689
Primary outcomes
What the sponsor says the trial is designed to measure.
- dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28 days after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.